Lupus therapeutic agents work by targeting different aspects of the immune system and reducing inflammation. Understanding the mechanisms of these agents is essential for optimizing their use in lupus therapeutic management.
NSAIDs and corticosteroids are non-specific agents that work by reducing inflammation and pain in a broad range of conditions. Antimalarials such as hydroxychloroquine are thought to work by modulating the immune response and reducing the production of autoantibodies in lupus. Immunosuppressive agents such as azathioprine and mycophenolate mofetil work by suppressing the immune system and reducing inflammation.
Biologics and small molecule inhibitors work by targeting specific molecules or pathways involved in the immune response. For example, belimumab targets BLyS, which is involved in the production of autoantibodies in lupus, while baricitinib targets the JAK pathway, which plays a role in inflammation. By targeting specific molecules or pathways, these agents can potentially achieve more targeted and effective control of lupus symptoms with fewer side effects.
In summary, understanding the mechanisms of lupus therapeutic agents is crucial for optimizing their use in lupus management and developing new treatments for this complex and challenging disease.
There have been shortages of certain lupus medications due to the increased demand and disruptions to supply chains. This has made it challenging for people with lupus to access the medications they need to manage their symptoms. Despite these challenges, healthcare providers have been working to adapt to the changing landscape of the COVID-19 pandemic and ensure that people with lupus can continue to receive the care they need. Telemedicine has become more widely used to provide remote consultations and monitor symptoms, and alternative treatment options have been explored when traditional therapies are not available.
Lupus is a complex disease and can present with a wide range of symptoms, which can vary from person to person. Common symptoms include hair loss, fever, skin rashes, swelling, joint pain, and fatigue. The severity of symptoms can also vary, ranging from mild to severe, and can be unpredictable.
According to a new study of FactMR, the gonorrhea therapeutics market will reach ~US$ 970 Mn in 2019, and estimated to register a 4% Y-o-Y over 2018.
The gonorrhea therapeutics industry will remain influenced by increased attention on new developments in novel therapeutic compounds or antimicrobials for improving the success potential of future treatment.There has been a significant rise in the prevalence of gonorrhea that is resistant to components of dual antibiotic therapy – ceftriaxone and azithromycin, which is the only recommended treatment for gonorrhea.
In addition, resistance to several other antibiotics apart from dual antibiotic therapy resulted in ‘super gonorrhea’, which has become a buzzword in the gonorrhea therapeutics market.
With a slew of promising new antibiotics on the horizon, alongside surveillance, education and preventative measures to stymie prevalence of super-resistant gonorrhea, prospects seem bullish for the gonorrhea therapeutics market.Request a free Sample Report - https://www.factmr.com/connectus/sample?flag=S_id=3761“As gonorrhea, a sexually transmitted bacterium is increasingly learning to withstand the currently available antibiotics, the infection is making progress in its relentless march towards untreatable status.
Growing partnerships between companies and organizations, to develop novel drugs that combat the drug-resistant gonorrhea, are highly likely to complement gains in the market,” says FactMR report.Dual Therapy Remains the Treatment of ChoiceThe market of gonorrhea therapeutics is likely to grow in parallel with the potentially effective drugs that are currently in pipeline.
This falls in line with the current recommended regimen for gonorrhea treatment that includes a combination of two antibiotics, azithromycin, which is given orally, and ceftriaxone, an intra-muscular drug.Gonorrhea Therapeutics Market research report Segmented By Drug Type (Macrolide Antibiotics, Third Generation Cephalosporin, Tetracycline Antibiotics, Fluoroquinolones Antibiotics, Aminoglycoside, Aminocyclitol), By Route of Administration (Oral, Intra Muscular), By Therapy Type (Mono Therapy, Dual Therapy), & by Region - https://www.factmr.com/report/3761/gonorrhea-therapeutics-marketAccording to the study, azithromycin will continue to account for greater gains in the gonorrhea treatment market, closely trailed by the third-generation cephalosporin that are increasing gaining traction.
